Key result
Antitroponin autoantibodies from DCM patients dose-dependently activate calcium-sensitive actomyosin ATPase in vitro.
Why the study?
Dilated cardiomyopathy is an organ-specific autoimmune disease characterized by autoantibodies against various cardiomyocyte proteins, but the biological activity of monospecific antitroponin autoantibodies was unclear.
Autoantibodies to cardiac troponin found in patients with dilated cardiomyopathy can activate actomyosin ATPase activity in vitro, suggesting a potential pathogenic role.
Answers are grounded in this paper and cite their sources.
May support pathogenic role of antitroponin autoantibodies in dilated cardiomyopathy; hypothesis-generating and leaves open in vivo relevance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fedorkova et al. (2003) studied Dilated cardiomyopathy (n=83). Antitroponin autoantibodies from DCM patients vs. Autoantibodies from healthy donors was evaluated on ATPase activity of calcium-sensitive actomyosin in vitro (p=<0.01). Monospecific antitroponin autoantibodies from patients with dilated cardiomyopathy exerted a dose-dependent activating influence on the ATPase activity of calcium-sensitive actomyosin in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: